Benefits of lisinopril therapy in cardiovascular and kidney diseases. Our expectations after HALT-PKD trial Review article
Article Sidebar
Published:
Dec 31, 2012
Keywords:
lisinopril, cardiovascular disease, kidney diseases, ADPKD
Main Article Content
Abstract
ACE-I (angiotensin converting-enzyme inhibitors) are one of the most important achievements of modern pharmacotherapy. Lisinopril is effective in the treatment of hypertension, in a monotherapy as well as in combination, in chronic heart failure, after acute coronary syndrome and in diabetic kidney disease. The results of ongoing the HALT-PKD study will try help to answer the question whether the optimal blood pressure control may slow the progression of chronic kidney disease, in all stages, or only in less advanced, and whether it is related to the prevalence of cardiovascular complications.
Article Details
How to Cite
Tomaszuk-Kazberuk, A., & Małyszko, J. (2012). Benefits of lisinopril therapy in cardiovascular and kidney diseases. Our expectations after HALT-PKD trial. Medycyna Faktow (J EBM), 5(4(17), 14-20. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2436
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Patchett A.A., Harris E., Tristram E.W. et al.: A new class of angiotensin-converting enzyme inhibitors. Nature 1980; 288: 280-283.
2. Opie L.H.: Inhibitory konwertazy angiotensyny. Postęp trwa. Via Medica, Gdańsk 2000: 219-223.
3. Barylski M., Górska-Ciebiada M.: Lizinopril – praktyczne wskazania do stosowania w terapii chorób układu sercowo-naczyniowego. Geriatria 2011; 5: 110-121.
4. Gu Q., Burt V.L., Dillon C.F. et al.: Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the national health and nutrition examination survey, 2001 to 2010. Circulation 2012; 126(17): 2105-2114.
5. Terpstra W.F., May J.F., Smit A.J. et al.: Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J. Hypertens. 2004; 22: 1309-1316.
6. Izzo J.L., Weinberg M.S., Hainer J.W. et al.: Antihypertensive Efficacy of Candersartan-Lisinopril in Combination vs Up-Titration of Lisinopril: The AMAZE Trials. J. Clin. Hypertens. 2004; 6: 485-93.
7. Malacco E., Santonastaso M., Vari N.A. et al.: Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin. Ther. 2004; 26: 855-65.
8. Belz G.G., Kirch W., Kleinbloesem C.H.: Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics. Clin. Pharmacokinet. 1988 Nov; 15(5): 295-318.
9. Shionoiri H., Ueda S., Gotoh E. et al.: Glucose and lipid metabolism during long-term lisinopril therapy in hypertensive patients. J. Cardiovasc. Pharmacol. 1990; 16(6): 905-9.
10. Thürig C., Böhlen L., Schneider M.: Lisinopril is neutral to insulin sensitivity and serum lipoproteins in essential hypertensive patients. Eur. J. Clin. Pharmacol. 1995; 49(1-2): 21-6.
11. Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Nadciśnienie Tętnicze 2011; 15: 55-82.
12. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
13. Lee A.F.C., Dick J.B.C., Bonnar C.E. et al.: Lisinopril improves arterial function in hyperlipidaemia. Clin. Scien. 1999; 96: 441-448.
14. Reisin E., Weir M.R., Falkner B. et al.: Lisinopril versus hydrochlorothiazide in obese hypertensive patients. A multicenter placebo-controlled trial. Hypertension 1997; 30 (part 1): 140-145.
15. Mogensen C.E., Neldam S., Tikkanen I. et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444.
16. Andersen N.H., Poulsen P.L., Knudsen S.T. et al.: Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care 2005; 28: 273-77.
17. Menne J., Farsang C., Deák L. et al.: Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial. J. Hypertens. 2008; 26: 1860-67.
18. The EUCLID Study Group: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349(9068): 1787-1792.
19. Chaturvedi N., Sjolie A.K., Stephenson J.M. et al.: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351: 28-31.
20. Brilla C.G., Funck R.C., Rupp H.: Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102: 1388-1393.
21. Beevers D.G., Blackwood R.A., Garnham S.: Comparison of lisinopril versus atenolol for mild to moderate essential hypertension. Am. J. Cardiol. 1991; 67(1): 59-62.
22. Jakubowski P., Drożdż J.: Inhibitory konwertazy angiotensyny w niewydolności serca. Terapia 2011; 3: 24-27.
23. Packer M., Poole-Wilson P.A., Armstrong P.W. et al.: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100(23): 2312-2318.
24. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Heart Journal 2012; 33: 1787-1847.
25. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343(8906): 1115-1122.
26. Popescu B.A., Macor F., Antonini-Canterin F. et al.: GISSI-3 Echo Substudy Investigators. Left atrium remodeling after acute myocardial infarction (results of the GISSI-3 Echo Substudy). Am. J. Cardiol. 2004; 93(9): 1156-1159.
27. Pizzettib F., Turazzaa F.M., Franzosia M.G. et al.: Cardiovascular medicine Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 2001; 86: 527-532.
28. Latini R., Santoro E., Masson S. et al.: GISSI-3 Investigators. Aspirin does not interact with ACE inhibitors when both are given early after acute myocardial infarction: results of the GISSI-3 Trial. Heart Dis. 2000; 2(3): 185-190.
29. Adamska-Dyniewska H.: Lizynopryl – hydrofilny inhibitor konwertazy angiotensyny. Leki współczesne, które warto znać. Wydawnictwo TTM, Łódź 2000: 94-107.
30. Savino L.B., Haushalter N.M.: Lisinopril-induced “scalded mouth syndrome”. Ann. Pharmacother. 1992; 26: 1381-1382.
31. Hateboer N., van Dijk M., Bogdanova N. et al.: Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 1999; 353(9147): 103-107.
32. Schrier R.: Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 2009; 20: 1888-1893.
33. Perrone R., Ruthazer R., Terrin N.: Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: Contribution of extrarenal complications to mortality. Am. J. Kidney Dis. 2001; 38: 777-784.
34. Fick G., Johnson A., Hammond W., Gabow P.: Causes of death in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 1995; 5: 2048-2056.
35. Chapman A.B., Torres V.E., Perrone R.D. et al.: The HALT polycystic kidney disease trials: design and implementation. Clin. J. Am. Soc. Nephrol. 2010; 5: 102-109.
36. Perrone R.D., Abebe K.Z., Schrier R.W. et al.: HALT PKD Study Group, Meyers C.M.: Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 2011; 6: 2508-2515.
37. Torres V.E., Chapman A.B., Perrone R.D., Bae K.T. et al.: HALT PKD Study Group. Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int. 2012; 81: 577-5785.
38. Torres V.E., Chapman A.B., Devuyst O. et al.: Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 2012 [online: doi: 10.1056/NEJMoa1205511].
2. Opie L.H.: Inhibitory konwertazy angiotensyny. Postęp trwa. Via Medica, Gdańsk 2000: 219-223.
3. Barylski M., Górska-Ciebiada M.: Lizinopril – praktyczne wskazania do stosowania w terapii chorób układu sercowo-naczyniowego. Geriatria 2011; 5: 110-121.
4. Gu Q., Burt V.L., Dillon C.F. et al.: Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the national health and nutrition examination survey, 2001 to 2010. Circulation 2012; 126(17): 2105-2114.
5. Terpstra W.F., May J.F., Smit A.J. et al.: Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J. Hypertens. 2004; 22: 1309-1316.
6. Izzo J.L., Weinberg M.S., Hainer J.W. et al.: Antihypertensive Efficacy of Candersartan-Lisinopril in Combination vs Up-Titration of Lisinopril: The AMAZE Trials. J. Clin. Hypertens. 2004; 6: 485-93.
7. Malacco E., Santonastaso M., Vari N.A. et al.: Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin. Ther. 2004; 26: 855-65.
8. Belz G.G., Kirch W., Kleinbloesem C.H.: Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics. Clin. Pharmacokinet. 1988 Nov; 15(5): 295-318.
9. Shionoiri H., Ueda S., Gotoh E. et al.: Glucose and lipid metabolism during long-term lisinopril therapy in hypertensive patients. J. Cardiovasc. Pharmacol. 1990; 16(6): 905-9.
10. Thürig C., Böhlen L., Schneider M.: Lisinopril is neutral to insulin sensitivity and serum lipoproteins in essential hypertensive patients. Eur. J. Clin. Pharmacol. 1995; 49(1-2): 21-6.
11. Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Nadciśnienie Tętnicze 2011; 15: 55-82.
12. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
13. Lee A.F.C., Dick J.B.C., Bonnar C.E. et al.: Lisinopril improves arterial function in hyperlipidaemia. Clin. Scien. 1999; 96: 441-448.
14. Reisin E., Weir M.R., Falkner B. et al.: Lisinopril versus hydrochlorothiazide in obese hypertensive patients. A multicenter placebo-controlled trial. Hypertension 1997; 30 (part 1): 140-145.
15. Mogensen C.E., Neldam S., Tikkanen I. et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444.
16. Andersen N.H., Poulsen P.L., Knudsen S.T. et al.: Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care 2005; 28: 273-77.
17. Menne J., Farsang C., Deák L. et al.: Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial. J. Hypertens. 2008; 26: 1860-67.
18. The EUCLID Study Group: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349(9068): 1787-1792.
19. Chaturvedi N., Sjolie A.K., Stephenson J.M. et al.: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351: 28-31.
20. Brilla C.G., Funck R.C., Rupp H.: Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102: 1388-1393.
21. Beevers D.G., Blackwood R.A., Garnham S.: Comparison of lisinopril versus atenolol for mild to moderate essential hypertension. Am. J. Cardiol. 1991; 67(1): 59-62.
22. Jakubowski P., Drożdż J.: Inhibitory konwertazy angiotensyny w niewydolności serca. Terapia 2011; 3: 24-27.
23. Packer M., Poole-Wilson P.A., Armstrong P.W. et al.: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100(23): 2312-2318.
24. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Heart Journal 2012; 33: 1787-1847.
25. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343(8906): 1115-1122.
26. Popescu B.A., Macor F., Antonini-Canterin F. et al.: GISSI-3 Echo Substudy Investigators. Left atrium remodeling after acute myocardial infarction (results of the GISSI-3 Echo Substudy). Am. J. Cardiol. 2004; 93(9): 1156-1159.
27. Pizzettib F., Turazzaa F.M., Franzosia M.G. et al.: Cardiovascular medicine Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 2001; 86: 527-532.
28. Latini R., Santoro E., Masson S. et al.: GISSI-3 Investigators. Aspirin does not interact with ACE inhibitors when both are given early after acute myocardial infarction: results of the GISSI-3 Trial. Heart Dis. 2000; 2(3): 185-190.
29. Adamska-Dyniewska H.: Lizynopryl – hydrofilny inhibitor konwertazy angiotensyny. Leki współczesne, które warto znać. Wydawnictwo TTM, Łódź 2000: 94-107.
30. Savino L.B., Haushalter N.M.: Lisinopril-induced “scalded mouth syndrome”. Ann. Pharmacother. 1992; 26: 1381-1382.
31. Hateboer N., van Dijk M., Bogdanova N. et al.: Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 1999; 353(9147): 103-107.
32. Schrier R.: Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 2009; 20: 1888-1893.
33. Perrone R., Ruthazer R., Terrin N.: Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: Contribution of extrarenal complications to mortality. Am. J. Kidney Dis. 2001; 38: 777-784.
34. Fick G., Johnson A., Hammond W., Gabow P.: Causes of death in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 1995; 5: 2048-2056.
35. Chapman A.B., Torres V.E., Perrone R.D. et al.: The HALT polycystic kidney disease trials: design and implementation. Clin. J. Am. Soc. Nephrol. 2010; 5: 102-109.
36. Perrone R.D., Abebe K.Z., Schrier R.W. et al.: HALT PKD Study Group, Meyers C.M.: Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 2011; 6: 2508-2515.
37. Torres V.E., Chapman A.B., Perrone R.D., Bae K.T. et al.: HALT PKD Study Group. Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int. 2012; 81: 577-5785.
38. Torres V.E., Chapman A.B., Devuyst O. et al.: Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 2012 [online: doi: 10.1056/NEJMoa1205511].